In plain English
Novo Nordisk A/S develops and sells medicines for diabetes, obesity, and related conditions, with a focus on GLP‑1 drugs like Ozempic and…
Company stock · NYSE · USD
NVO
Novo Nordisk A/S
—
Price unavailable — company details still show below
- Sector
- Other
- Industry
- Pharmaceuticals
- Size
- Large company
- Market value
- $1.17 trillion
- Number of shares
- 3.39 billion
- Country
- DK
- Went public
- May 17, 1974
- Exchange
- NYSE
- Website
- novonordisk.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What NVO is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
7 recent cards — open any for the full deeper dive.
Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
In brief
Novo’s FDA approval of Awiqli® introduces the first once‑weekly insulin for children, opening a new revenue stream and strengthening its diabetes portfolio.
Novo provides update on the denecimig Biologics License Application (BLA) in the US
In brief
Denecimig’s U.S. launch is pushed to early 2027 due to FDA‑required manufacturing site remediation, but Novo says the delay won’t hurt its 2026 earnings.
Novo Nordisk A/S - share repurchase programme
In brief
Novo Nordisk is using its cash flow to buy back up to DKK 15 billion of B shares, reducing share count and supporting the stock price.
Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He Bought
In brief
Franklin is pivoting from tech to consumer staples, hinting he sees better upside in stable‑income businesses as inflation pressures ease.
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
In brief
EU approval of FREHEMGO® could give patients a more convenient, low‑bleed‑risk option and boost Novo’s haemophilia business.
Novo Nordisk, Anthropic Team Up For AI Drug Research
In brief
Novo Nordisk’s new AI partnership with Anthropic could accelerate drug discovery and strengthen its competitive position in biopharma.
Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients
In brief
Amazon Pharmacy's new program offers affordable access to weight-loss drugs for Medicare beneficiaries, potentially attracting more customers and establishing a relationship with patients.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for NVO will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.